SCHEDULE 13G/A: BlackRock Discloses 7.3% Passive Stake in Sutro Biopharma

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.3% beneficial ownership stake in Sutro Biopharma, Inc. as of March 31, 2025, indicating a passive investment.

Summary

• BlackRock, Inc. reported beneficial ownership of 6,143,608 shares of Sutro Biopharma, Inc. common stock.
• This ownership represents 7.3% of Sutro Biopharma's common stock outstanding.
• The filing is an Amendment No. 4 to a Schedule 13G, indicating an update to a previously disclosed passive stake.
• BlackRock holds sole voting power over 6,040,133 shares and sole dispositive power over 6,143,608 shares.
• The securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Sutro Biopharma.
• Various BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are involved in the beneficial ownership, with at least one entity owning 5% or more of the outstanding shares.

Sentiment

Score: 6

Explanation: The document is a routine compliance filing indicating a significant, passive institutional investment. While not directly positive for the company's operations, it reflects continued institutional confidence and transparency in reporting, which is generally viewed favorably.

Positives

• Increased institutional ownership by a major asset manager like BlackRock can signal confidence in the company's long-term prospects.
• The passive nature of the investment (13G filing) suggests BlackRock is not seeking to influence management, which can be viewed positively by current management and other shareholders.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Sutro Biopharma, Inc.'s future performance or BlackRock's future investment intentions beyond the passive nature of the current holding.

Management Comments

• The filing includes a certification from BlackRock, Inc. stating that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing reflects a routine disclosure by a major institutional asset manager, BlackRock, Inc., regarding its passive investment in a biopharmaceutical company, Sutro Biopharma. Such disclosures are common as large funds manage diversified portfolios, and their holdings often exceed the 5% threshold requiring public reporting. It indicates continued institutional interest in the biopharma sector.

Comparison to Industry Standards

• As a routine Schedule 13G filing, this document primarily serves as a compliance disclosure of beneficial ownership by a large institutional investor. It does not provide specific operational or financial results for Sutro Biopharma that would allow for direct comparison to industry-specific benchmarks or competitor performance.
• However, BlackRock's continued holding of a significant stake is consistent with its role as a major passive investor across various industries, including biotechnology.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional holder's stake. The passive nature of the investment suggests no immediate intent to influence corporate strategy, which may provide stability.
• Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this ownership disclosure.

Key Dates

Keywords

Sutro Biopharma, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Biopharma, STRP